Alpharma, Shasun ink generic drug pact

New Jersey-based Alpharma will provide development funding to India's Shasun Chemicals as part of a marketing pact to distribute generic drugs in the US and Europe. Shasun will manufacture 10 generic drugs for a variety of conditions -- including cardiovascular conditions -- with a cumulative market value of $20 billion.

- read this article from the Business-Standard for more

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.